These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: A small-scale open-label study of the treatment of canine flea allergy dermatitis with fluralaner.
    Author: Fisara P, Shipstone M, von Berky A, von Berky J.
    Journal: Vet Dermatol; 2015 Dec; 26(6):417-20, e97-8. PubMed ID: 26271195.
    Abstract:
    BACKGROUND: Fluralaner is an isoxazoline systemic insecticide and acaricide that provides persistent flea-killing activity on dogs for 12 weeks. European and US field studies have shown that fluralaner treatment alleviates the signs of flea allergy dermatitis (FAD) in client-owned dogs. HYPOTHESIS/OBJECTIVE: To assess the clinical response in FAD affected dogs over the 12-week period following a single oral fluralaner treatment. ANIMALS: Twenty client-owned dogs were diagnosed with FAD on the basis of compatible clinical signs and a positive response in flea antigen tests, using intradermal and or serological methods. METHODS: An open-label small-scale study with all dogs receiving a single oral fluralaner treatment. All enrolled dogs were diagnosed with FAD and then clinically monitored at 4-week intervals for 12 weeks. Twenty dogs completed the study. RESULTS: All dogs were flea-free at all post-treatment assessments except for one dog that had a single flea at the first post-enrollment assessment at 4 weeks. At the 4-week post-treatment assessment active FAD signs had resolved in all dogs; at 8 weeks post-treatment, two dogs showed mild signs. All clinical signs of FAD had resolved at the final assessment of 12 weeks after treatment. CONCLUSIONS AND CLINICAL IMPORTANCE: A single administration of fluralaner alleviated or resolved signs associated with FAD in all treated dogs over the recommended 12-week treatment period.
    [Abstract] [Full Text] [Related] [New Search]